SRRA - SRRA STOCK NEWS

Menlo Park, Calif. — Frazier Life Sciences appointed Angie You, Ph.D., as Senior Advisor following her tenure as CEO of Amunix Pharmaceuticals, acquired by Sanofi for up to $1.225 billion. Dr. You previously held key roles at Sierra Oncology (NASDAQ: SRRA), where she contributed to a successful IPO and pipeline development. With a Ph.D. in Biochemistry from Harvard, her extensive experience in biopharmaceuticals will aid Frazier in identifying investment opportunities. Frazier Life Sciences has raised over $2.1 billion and supported 61 IPOs or M&As since 2005.

Sierra Oncology (NASDAQ: SRRA) has granted a stock option of 27,000 shares to a new employee under its 2018 Equity Inducement Plan. The exercise price is set at $30.85 per share, matching the closing stock price at the time of the grant. This option vests 25% on the first anniversary of employment, with the remaining shares vesting over 36 months, contingent on the employee's continued employment. Sierra Oncology is focused on developing targeted therapies for rare cancers, leveraging their scientific expertise to innovate cancer treatment.

Sierra Oncology (SRRA), a late-stage biopharmaceutical company, granted a stock option to a new employee as per its 2018 Equity Inducement Plan. The employee received options for 10,500 shares at an exercise price of $29.65, aligning with the stock's closing price on the grant date. These options will vest over four years, with 25% on the first anniversary and the remainder in 36 equal monthly installments, contingent on the employee's continued employment. This initiative indicates Sierra's commitment to attracting and retaining talent critical to its mission of developing targeted cancer therapies.

Sierra Oncology, Inc. (Nasdaq: SRRA) announced that underwriters fully exercised their option to purchase an additional 750,000 shares at $27.00 each, raising approximately $155.3 million in gross proceeds. The offering closed on February 3, 2022. The funds will support the commercialization of momelotinib, clinical development of other product candidates, and general corporate purposes. Jefferies and Cantor acted as joint book-running managers for the offering. This follows a previously effective shelf registration statement filed with the SEC.

Sierra Oncology, Inc. (NASDAQ: SRRA) will participate in the 4th Annual Guggenheim Oncology Conference, held virtually from February 9-11, 2022. The company's President and CEO, Stephen Dilly, will engage in an analyst-moderated fireside chat on February 10, 2022, at 12:00 pm ET. A replay will be accessible on Sierra's corporate website for 30 days post-conference. Sierra Oncology focuses on delivering targeted therapies for rare cancers, leveraging advanced scientific expertise to transform cancer treatment.

Sierra Oncology, Inc. (NASDAQ: SRRA) has completed a public offering of 4,074,075 shares at $27.00 each and 925,925 pre-funded warrants at $26.999. The gross proceeds are approximately $135.0 million, with net proceeds around $126.6 million after expenses. Sierra plans to use these funds for the commercialization of momelotinib, clinical development of other products, and general corporate purposes. Jefferies and Cantor acted as joint book-running managers for this offering.

Sierra Oncology (NASDAQ: SRRA), a late-stage biopharmaceutical firm focused on rare cancers, will participate in the B. Riley Securities Oncology Investor Conference on January 27-28, 2022. CEO Stephen Dilly will present an overview of the company on January 28 at 2:30 pm ET. A replay of this presentation will be available for 30 days on Sierra's website in the Events & Webcast section. Sierra is committed to transforming cancer treatments through targeted therapies, utilizing scientific expertise to advance innovative solutions for patients.

Sierra Oncology, Inc. (NASDAQ: SRRA) announced a public offering of 4,074,075 shares of common stock priced at $27.00 each, along with pre-funded warrants for 925,925 shares at $26.999. The offering is expected to generate approximately $135 million before expenses. A 30-day option for underwriters to purchase an additional 750,000 shares is included. Proceeds will fund the commercialization of momelotinib, clinical development of other candidates, and general corporate purposes. The offering is set to close around January 31, 2022.

Sierra Oncology, Inc. (NASDAQ: SRRA) announced plans to offer and sell $100.0 million of common stock in an underwritten public offering. Subject to market conditions, the offering may include an additional $15.0 million in shares. Proceeds are intended for potential commercialization of momelotinib, clinical development of other candidates, and general corporate purposes. Jefferies and Cantor are joint book-running managers for the offering, with a shelf registration effective since November 2021. Details will be available via the SEC.